Transplant News stories from June, 2019

Study Published in Journal of Clinical Investigation Insight Demonstrates Ability to Predict Early Rejection in Kidney Transplant with FractalDx Portfolio Technology

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that positive study results have been published in the Journal of Clinical Investigation (JCI) Insight1. These results show FractalDx portfolio technology can accurately predict early acute kidney rejection in transplant patients. Early detection of acute transplant rejection is a critical unmet medical need that directly effects transplant success and long-term patient survival. In addition, the published results suggest that FractalDx can be used to personalize and potentially optimize the administration of immunosuppression therapy in kidney transplant patients. This could mitigate toxic side effects and damage to the transplanted kidney arising from excessive dosing.

Read More

Patient Advocates Commend CMS for Maintaining Medicare’s Six Protected Classes Policy

As designed by Congress, Medicare’s six protected classes policy guarantees access to treatments for Medicare patients with the most complex conditions, including cancer, HIV/AIDS, mental health conditions, epilepsy, organ transplants, and Parkinson’s   Washington D.C. — The Partnership for Part D Access, a broad-based coalition of health care stakeholders including over 20 diverse patient advocacy

Read More